NYSE:PLX

Protalix Biotherapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy PLX

*Your capital is at risk

$2.37

+0.100 (+4.41%)

At Close: Jul 31, 2026

Protalix BioTherapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 99.95. In total, the insiders bought 10.51M and sold 168 PLX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	99.95
● Buy	10.51M shares
● Sell	168 shares
99% Buy Activity Moderate Positive Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Sep 03, 2025 Buy	Stock Options (Right to Buy) A-Award	Bar-shalev Amos Director	Director	15 000 Value: $24.6K
Sep 03, 2025 Buy	Common Stock A-Award	Ben Zvi Shmuel Director	Director	7 500 Value: $12.0K
Sep 03, 2025 Buy	Stock Options (Right to Buy) A-Award	Ben Zvi Shmuel Director	Director	15 000 Value: $24.6K
Sep 03, 2025 Buy	Common Stock A-Award	Elze Christian Director	Director	7 500 Value: $12.0K
Sep 03, 2025 Buy	Common Stock A-Award	Schwartz Aharon Director	Director	7 500 Value: $12.0K
Sep 03, 2025 Buy	Stock Options (Right to Buy) A-Award	Elze Christian Director	Director	15 000 Value: $24.6K
Sep 03, 2025 Buy	Stock Options (Right to Buy) A-Award	Schwartz Aharon Director	Director	15 000 Value: $24.6K
Sep 03, 2025 Buy	Common Stock A-Award	Boudes Pol F Director	Director	7 500 Value: $12.0K
Sep 03, 2025 Buy	Stock Options (Right to Buy) A-Award	Boudes Pol F Director	Director	15 000 Value: $24.6K
Sep 03, 2025 Buy	Common Stock A-Award	Melincoff Gwen A Director	Director	7 500 Value: $12.0K
Sep 03, 2025 Buy	Common Stock A-Award	Forster Eliot Director	Director	7 500 Value: $12.0K
Sep 03, 2025 Buy	Stock Options (Right to Buy) A-Award	Forster Eliot Director	Director	15 000 Value: $24.6K
Sep 03, 2025 Buy	Stock Options (Right to Buy) A-Award	Melincoff Gwen A Director	Director	15 000 Value: $24.6K
Aug 24, 2025 Buy	Common Stock	Mamlok Gilad Sr. Vp And CFO	C-Suite Officer	0 Value: $0
Aug 24, 2025 Buy	Stock Option (Right to Buy)	Mamlok Gilad Sr. Vp And CFO	C-Suite Officer	597 990 Value: $867.1K
Aug 24, 2025 Buy	Stock Option (Right to Buy)	Mamlok Gilad Sr. Vp And CFO	C-Suite Officer	597 990 Value: $867.1K
Jun 26, 2025 Buy	Common Stock J-Other	Elze Christian Insider	Other	0 Value: $0
Jun 26, 2025 Buy	Common Stock J-Other	Elze Christian Insider	Other	0 Value: $0
Jun 10, 2025 Buy	Common Stock P-Purchase	Schwartz Aharon Director	Director	129 000 Value: $205.9K
Jun 10, 2025 Buy	Common Stock P-Purchase	Schwartz Aharon Director	Director	129 000 Value: $205.9K
Sep 23, 2024 Buy	Common Stock A-Award	Rubin Eyal Sr. Vp And CFO	C-Suite Officer	90 909 Value: $101.8K
Sep 23, 2024 Buy	Common Stock A-Award	Rubin Eyal Sr. Vp And CFO	C-Suite Officer	90 909 Value: $101.8K
Sep 23, 2024 Buy	Common Stock A-Award	Rubin Eyal Sr. Vp And CFO	C-Suite Officer	99 010 Value: $110.9K
Sep 23, 2024 Buy	Stock Option (Right to Buy) A-Award	Naos Yaron Sr. Vp, Operations	Officer	100 000 Value: $110.0K
Sep 23, 2024 Buy	Stock Option (Right to Buy) A-Award	Naos Yaron Sr. Vp, Operations	Officer	100 000 Value: $110.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT PROTALIX BIOTHERAPEUTICS INC

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candi...

Read Full Profile Here